AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection

Published: 16 November 2023

Views:
1338
Likes:
7

Views:
1338
Likes:
7
Share:

Now Playing
Part 1 | Session 8 of 10
An Extended Duration Short-Interfering RNA Targeting Lp(a)
Maryam Barkhordarian, Steven E Nissen

Up Next
11m 15s

Part 1 | Session 9 ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin
Naima Maqsood, Jeff Healey
15m 26s

Part 1 | Session 10 ARIES HM3: Avoidance of Aspirin with LVAD Devices
Mandeep Mehra, Christian Inchaustegui

14m 58s

Part 1 | Session 1 ORBITA-2: PCI for Stable Angina Rasha Al-Lamee, Nazli Okumus, Christopher Rajkumar

11m 47s

Part 1 | Session 2 SELECT: Effects of Semaglutide on Heart Disease & Stroke in Obese Patients A Michael Lincoff , Ahmed Ghoneem

16m 5s

Part 1 | Session 3 MINT: Myocardial Ischaemia & Transfusion Nazli Okumus, Jeffrey L Carson

11m 41s

Part 1 | Session 4 KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension George L Bakris, Sukriti Banthiya

8m 35s

Part 1 | Session 5 CordiO App: Speech Analysis to Detect Worsening HF in ADHF Patients Hanad Bashir, William T Abraham

14m 32s

Part 1 | Session 6 AHA23: Presidential Advisory on Cardiovascular-Kidney-Metabolic Health Ramy Doss, Chiadi E Ndumele

10m 36s

Part 1 | Session 7 AZALEA-TIMI 71: Abelcibab Vs Rivaroxaban in Patients with AF Naima Maqsood, Christian Ruff

Average (ratings)

No ratings

Your rating

Overview

In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.

These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.

More from this programme

Part 1

Radcliffe & Cardionerds @AHA23

10 sessions
ORBITA-2: PCI for Stable Angina	Watch now
SELECT: Effects of Semaglutide on Heart Disease & Stroke in Obese Patients	Watch now
MINT: Myocardial Ischaemia & Transfusion	Watch now
KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension	Watch now
CordiO App: Speech Analysis to Detect Worsening HF in ADHF Patients	Watch now
AHA23: Presidential Advisory on Cardiovascular-Kidney-Metabolic Health	Watch now
AZALEA-TIMI 71: Abelcibab Vs Rivaroxaban in Patients with AF	Watch now
An Extended Duration Short-Interfering RNA Targeting Lp(a)	Watch now
ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin	Watch now
ARIES HM3: Avoidance of Aspirin with LVAD Devices	Watch now

About the episode

AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).

The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is to investigate the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). Investigators enrolled 254 participants with Lp(a) ≥175 nmol/L.

Findings showed that subcutaneous injection of lepodisiran substantially lowered lipoprotein(a). After the 608mg dose, serum concentrations of lipoprotein(a) fell below the lower limit of quantitation from days 29 to 281 and remained below baseline for 48 weeks. No major safety issues were observed, although low-grade injection site reactions occurred.

Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

Faculty Biographies

Maryam Barkhordarian

Maryam Barkhordarian, currently an internal medicine resident at Hackensack Meridian Health-Palisades Medical Center in New Jersey, has a noteworthy background in the field of cardiology. She initially joined the CardioNerds academy as an intern, actively involved in editing their podcasts. Her dedication to medical education and cardiology has led her to her current role as a medical education fellow with CardioNerds. Her dedication not only defines her past contributions but also toward her ambition to cardiology fellowship.

View full profile